Jenny Yip, Managing Partner at Adjuvant Capital, invests $100K–$5.0M (sweet spot $1.5M) in mid-to-late-stage life. See sector focus and contact routes.
Jenny Yip, Managing Partner at Adjuvant Capital, invests $100K–$5.0M (sweet spot $1.5M) in mid-to-late-stage life sciences targeting high-burden infectious diseases, sexual/reproductive health, and maternal/child health in low- and middle-income countries. Her distinctive thesis fills a capital gap for affordable drugs, vaccines, diagnostics, and devices addressing neglected diseases like HIV, malaria, and tuberculosis to deliver both social impact and top-tier returns. Notable portfolio companies include Excision BioTherapeutics (CRISPR-based HIV therapies), 54Gene (Africa’s first biobank), Evofem Biosciences (women’s health/contraception), and ChromaCode, with Yip serving on several boards.
StartupFundraising tracks this investor record from SEC filings and announced rounds, updating focus, location and portfolio history as new data lands. Use it to gauge fit before an outreach, then widen the search to investors in New York.
Investors like Jenny Yip · Full investor directory · Investor access · Company funding database